EX-10.1


   

  Exhibit 10.1

  Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

  AMENDMENT NO. AR3 TO 

  AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT

  This Amendment No. AR3 to the Amended and Restated Collaboration and License Agreement (the “Amendment No. AR3”), effective as of January 27, 2022 (the “Amendment No. AR3 Effective Date”), is by and between D. E. Shaw Research, LLC, a Delaware limited liability company located at 120 West 45th Street, 39th Floor, New York, NY 10036 (“DESRES”), and Relay Therapeutics, Inc., a Delaware corporation located at 399 Binney Street, Cambridge, MA 02139 (“Company”).  DESRES and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties”.

   

  WHEREAS, DESRES and Company are parties to the Amended and Restated Collaboration and License Agreement, effective as of June 15, 2020, as amended by Amendment No. AR1 effective as of February 4, 2021, and by Amendment No. AR2 effective as of May 12, 2021 (collectively, the “Agreement”); 

  WHEREAS, the Parties desire to re-categorize certain Targets by mutual agreement, as set forth below;

  	NOW THEREFORE, the Parties agree, in accordance with Section 17.4 of the Agreement, as follows:

  1.On and after the Amendment No. AR3 Effective Date, by mutual agreement of the Parties:


  1.1	pursuant to Section 4.7(e) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 3 Targets, shall be Category [***] Targets:

   

  		[***]

   

  1.2	pursuant to Section 4.7(e) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 3 Targets, shall be Category [***] Targets:

   

  		[***]

   

  1

   

   

   

  

   

  1.3	pursuant to Section 4.7(d) of the Agreement, the following Targets, which, prior to the Amendment No. AR3 Effective Date, had been Category 2 Targets, shall be Category 3 Targets:

   

  		[***]

   

  2.Exhibit A-1 and Exhibit A-2 are each hereby amended, in the form attached hereto, to reflect the provisions of Section 1 of this Amendment No. AR3.


  3.Capitalized terms used in this Amendment No. AR3 and not defined herein shall have the respective meanings given to such terms in the Agreement.  


  4.This Amendment No. AR3 does not amend any terms of the Agreement except as explicitly set forth herein.  After the Amendment No. AR3 Effective Date, references to the “Agreement” shall mean the Amended and Restated Collaboration and License Agreement by and between the Parties effective as of June 15, 2020, as amended by Amendment No. AR1, Amendment No. AR2, and this Amendment No. AR3.


  5.Counterparts.  This Amendment No. AR3 may be executed in any number of counterparts, each of which will be deemed an original, but all of which taken together shall constitute one single agreement between the Parties.  This Amendment No. AR3 may be executed by the exchange of signature pages in electronic format (including PDF) or digital signatures.


   

  [Signature Page Follows]

   

  2

   

   

   

  

   

   

  IN WITNESS WHEREOF, the Parties have caused this Amendment No. AR3 to be executed by their duly authorized representatives.

   

  		
	D. E. Shaw Research, LLC
	Relay Therapeutics, Inc.

	By: /s/ Jennifer McGrady                       
	By: /s/ Brian Adams                          

	Name: Jennifer McGrady
	Name:  Brian Adams

	Title: Authorized Signatory
	Title:  Chief Legal Officer



   

   

  3

   

   

   

  

   

   

  Exhibit A-1: Category 1 Targets

  (on and after the Amendment No. AR3 Effective Date)

   

  [***]

   

  4

   

  

   

   

  Exhibit A-2: Category 2 Targets

  (on and after the Amendment No. AR3 Effective Date)

   

  [***]

  5